Korean Medication Algorithm Project for Bipolar Disorder 2022: Comorbid Physical Illnesses
10.4306/jknpa.2022.61.4.267
- Author:
Myung Hun JUNG
1
;
Won-Myong BAHK
;
Young Sup WOO
;
Jong-Hyun JEONG
;
Bo-Hyun YOON
;
Jeong Seok SEO
;
Chan-Mo YANG
;
Won KIM
;
Jung Goo LEE
;
Se-Hoon SHIM
;
IL Han CHOO
;
Sung-Yong PARK
;
InKi SOHN
;
Duk-In JON
;
Moon-Doo KIM
Author Information
1. Department of Psychiatry, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Journal of Korean Neuropsychiatric Association
2022;61(4):267-273
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objectives:The present study was carried out to revise the guidelines for the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2018. The revision was carried out based on expert opinions to facilitate clinical decisions related to the treatment of bipolar disorders in patients with comorbid physical illnesses.
Methods:A 56-item questionnaire was developed; a consensus was arrived at by 87 out of 93 experts (93.5%), on the pharmacological treatment strategies to be used in cases of comorbid physical illnesses accompanying bipolar disorders.
Results:For patients with bipolar disorder exhibiting comorbid conditions, by consensus, lamotrigine, aripiprazole, and ziprasidone were recommended as the first-line strategies for metabolic syndrome; lamotrigine and aripiprazole were the recommended first-line strategies for cardiovascular problems; lithium and aripiprazole were the recommended first-line strategies for haptic problems; valproate, lamotrigine, aripiprazole, and quetiapine were the recommended first-line strategies for renal problems; and valproate and aripiprazole were the recommended first-line strategies for cerebrovascular problems or cerebral damage.
Conclusion:The present study is the most recent consensus among experts on recommendations for the treatment of bipolar disorders in patients with comorbid physical illnesses. Aripiprazole was recommended as the first-line pharmacotherapeutic agent in five comorbid physical conditions. This recommendation is similar to KMAP-BP 2018. Additionally, lamotrigine has been added as a first -line pharmacotherapeutic agent in patients with the metabolic syndrome, cardiovascular problems, and renal problems in the current algorithm.
